Storen Legacy Partners’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$278K Sell
1,062
-57
-5% -$14.6K 0.07% 97
2026
Q2
$282K Buy
1,119
+35
+3% +$7.53K 0.08% 91
2026
Q1
$236K Buy
1,084
+4
+0.4% +$887 0.07% 91
2025
Q4
$247K Hold
1,080
– – 0.08% 67

Other funds holding ABBV

Storen Legacy Partners's ABBV Position: Q3 2026 in Review

Storen Legacy Partners reduced its AbbVie (ABBV) stake by 5.1% in Q3 2026, selling an estimated $14.6K and leaving 1,062 shares worth $278K. The position accounts for 0.07% of the portfolio, ranked #97.

Storen Legacy Partners first reported a position in ABBV in Q4 2025 and has held it in 4 quarters since. The position peaked at $282K in Q2 2026. 4,281 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Storen Legacy Partners held 1,062 shares of AbbVie worth $278K as of Q3 2026.
  • Storen Legacy Partners sold 57 AbbVie shares in Q3 2026, an estimated $14.6K.
  • AbbVie made up 0.07% of Storen Legacy Partners's portfolio in Q3 2026, its #97 holding.
  • Storen Legacy Partners first reported a position in AbbVie in Q4 2025 and has held it in 4 quarters since.
  • Storen Legacy Partners's AbbVie position peaked at $282K in Q2 2026.
  • 4,281 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Storen Legacy Partners's 13F filing for Q3 2026, filed 9 Nov 2026.